LUMO Lumos Pharma, Inc.Stock Price & Overview
$3.090.07 (+2.32%)3:57 PM 11/27/23
NASDAQ | $USD | Post-Market: $3.09 4:00 PM
People Also Follow
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.